Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INFI
  • CUSIP: 45665G30
  • Web:
  • Market Cap: $147 million
  • Outstanding Shares: 50,689,000
Average Prices:
  • 50 Day Moving Avg: $1.35
  • 200 Day Moving Avg: $1.63
  • 52 Week Range: $0.84 - $3.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.17
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.17 per share
  • Price / Book: 2.52
  • EBITDA: ($55,730,000.00)
  • Return on Equity: -88.08%
  • Return on Assets: -59.20%
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 6.29%
  • Quick Ratio: 6.29%
  • Average Volume: 2.17 million shs.
  • Beta: 2.63
  • Short Ratio: 4

Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.12. During the same period in the prior year, the business posted $1.05 earnings per share. View Infinity Pharmaceuticals' Earnings History.

When will Infinity Pharmaceuticals make its next earnings announcement?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totalling 908,639 shares, a drop of 22.5% from the August 15th total of 1,172,061 shares. Based on an average daily trading volume, of 658,966 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.9% of the company's shares are short sold.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:

  • Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer
  • Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer
  • William C. Bertrand Jr. Esq., Executive Vice President, General Counsel
  • Melissa Hackel, Vice President - Finance
  • Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
  • Norman C. Selby, Lead Outside Independent Director
  • Jeffrey Berkowitz J.D., Independent Director
  • Anthony B. Evnin Ph.D., Independent Director
  • Michael G. Kauffman M.D., Ph.D., Independent Director
  • Ian F. Smith CPA, Independent Director

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $2.95.

MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A
Consensus Price Target History for Infinity Pharmaceuticals (NASDAQ:INFI)
Price Target History for Infinity Pharmaceuticals (NASDAQ:INFI)
Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00N/AView Rating Details
6/15/2016Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00N/AView Rating Details
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.20)N/AView Earnings Details
8/3/2017Q2 2017($0.22)($0.34)ViewListenView Earnings Details
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
2017 EPS Consensus Estimate: ($0.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.23)($0.13)($0.18)
Q2 20172($0.21)($0.12)($0.17)
Q3 20172($0.21)($0.13)($0.17)
Q4 20172($0.21)($0.13)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 67.47%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Value Fund L P BiotechnologyInsiderBuy1,600,046$1.26$2,016,057.96View SEC Filing  
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.00View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.00View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.70View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
DateHeadline logoInfinity Pharmaceuticals, Inc. (INFI) Stock Rating Upgraded by Wells Fargo & Company - October 15 at 8:30 AM logoInfinity Pharma (INFI) Announces IPI-549 Late-Breaking Presentation at SITC - October 13 at 7:42 PM logoInfinity Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting - October 13 at 7:42 PM logoInfinity Pharma up big but news scarce; shares ahead 90% - Seeking Alpha - October 13 at 2:33 AM logoWhy Infinity Pharmaceuticals Shares Are Surging - 24/7 Wall St. - October 13 at 2:33 AM logoMid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher - Nasdaq - October 13 at 2:33 AM logoInfinity Pharmaceuticals: Oral Presentation Implies Near-Term Upside - Seeking Alpha - October 13 at 2:33 AM logoInfinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation - October 13 at 2:33 AM logoInfinity Pharmaceuticals, Inc. (INFI) Upgraded to Sell at ValuEngine - October 12 at 11:16 PM logoMid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher - October 12 at 3:14 PM logoInfinity To Present At The 2017 BIO Investor Forum - October 10 at 7:15 PM logoInfinity Pharmaceuticals, Inc. (INFI) Insider Acquires $2,016,057.96 in Stock - October 5 at 10:28 PM logoStocks Under Scanner in the Biotech Space -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - October 5 at 9:02 AM logoAnalyzing Infinity Pharmaceuticals (INFI) & Its Rivals - October 3 at 10:56 AM logoHarvard's IT unit taking Cambridge office after Infinity Pharma exits lease - Boston Business Journal - September 26 at 4:59 PM logoInfinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal - September 26 at 10:26 AM logoInfinity Pharma (INFI) & Bristol-Myers Squibb Report Expansion of Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab) - September 25 at 6:27 PM logoInfinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study - September 25 at 6:27 PM logoBRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration - September 25 at 6:27 PM logoInfinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 in Combination ... - PR Newswire (press release) - September 25 at 9:36 AM logoInfinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab) - September 25 at 9:36 AM logoInfinity Pharmaceuticals, Inc. (INFI) Short Interest Update - September 17 at 1:20 AM logoFinancial Analysis: Infinity Pharmaceuticals (INFI) vs. RXi Pharmaceuticals Corporation (RXII) - September 10 at 6:26 PM logoInfinity Pharmaceuticals, Inc. (INFI) Expected to Post Earnings of -$0.21 Per Share - September 5 at 6:14 AM logo-$0.21 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter - August 17 at 8:26 PM logoInfinity (INFI) Q2 Loss Wider than Expected, View Intact - Nasdaq - August 6 at 4:44 AM logoInfinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 6 at 4:44 AM logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Issues Quarterly Earnings Results - August 5 at 8:22 PM logoEdited Transcript of INFI earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 8:10 PM logoInfinity (INFI) Q2 Loss Wider than Expected, View Intact - August 4 at 8:10 PM logoBRIEF-Infinity Q2 loss per share $0.34 - August 3 at 8:00 PM logoInfinity Provides Company Update and Reports Second Quarter 2017 Financial Results - August 3 at 8:00 PM logoInfinity reports 2Q loss - August 3 at 8:00 PM logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Recommendation of "Hold" by Brokerages - August 1 at 12:34 PM logoInfinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda - July 29 at 6:49 PM logoInfinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda - - July 28 at 3:41 AM logoInfinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology - July 27 at 10:40 PM logoFinancial Survey: Celator Pharmaceuticals (CPXX) versus Infinity Pharmaceuticals (INFI) - July 21 at 6:06 PM logoInfinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast - July 21 at 3:58 PM logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Rating of "Hold" by Brokerages - July 7 at 12:44 PM logoCompany Spotlight: Verastem - July 7 at 6:29 AM logoInfinity to Participate in Three Upcoming Conferences - PR Newswire (press release) - June 15 at 6:13 AM logoInfinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - Nasdaq - June 14 at 11:23 AM logoVerastem Reports First Quarter 2017 Financial Results - May 10 at 6:21 PM logoInfinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release) - May 10 at 1:18 PM logoInfinity reports 1Q loss - May 9 at 5:44 PM logoBRIEF-Infinity reports Q1 loss per share $0.21 - May 9 at 5:43 PM logoVerastem Boosts Oncologic Drug Portfolio, Fuels Stock Price - May 7 at 6:18 PM logoRegeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates - May 4 at 6:05 PM logoAbbVie (ABBV) Presents Positive Data on HCV Combination Drug - April 21 at 10:39 AM



Infinity Pharmaceuticals (INFI) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.